Research Topics
Species | Richard C KoyaSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapyRichard C Koya
Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Cancer Res 72:3928-37. 2012..Taken together, our findings, derived from 2 independent models combining BRAF-targeted therapy with immunotherapy, support the testing of this therapeutic combination in patients with BRAFV600 mutant metastatic melanoma...- Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responsesRichard C Koya
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, CA 90095, USA
Proc Natl Acad Sci U S A 107:14286-91. 2010..This approach of TCR engineering and molecular imaging reporter gene labeling is directly translatable to humans and provides useful information on how to clinically develop this mode of therapy... 
Immunosensitization with a Bcl-2 small molecule inhibitorJonathan Begley
Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
Cancer Immunol Immunother 58:699-708. 2009....
Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccinesRichard C Koya
Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Mol Ther 15:971-80. 2007..Thus, DC precursors can be genetically engineered after a single ex vivo manipulation, resulting in DC vaccines with improved activity...- Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expressionTakahiro Kimura
Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
Mol Ther 15:1390-9. 2007..These studies reveal that APC transduction by LVs could lead to immune reactivity (LV-CMV) or persistence of transgene expression (LV-MHCII), providing a relevant paradigm for vaccination and gene replacement approaches... - Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell linesErika von Euw
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, Los Angeles, CA, USA
Mol Cancer 11:22. 2012..TAK733 is a novel allosteric, non-ATP-binding, inhibitor of the BRAF substrates MEK-1/2... - The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapyPaul C Tumeh
Division of Hematology Oncology, Department of Medicine, University of California Los Angeles UCLA, Los Angeles, California, USA
J Immunother 33:759-68. 2010.... - Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitorsHubing Shi
Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California 90095 1750, USA
Cancer Discov 2:414-24. 2012..We identify here concurrent activating mutations in BRAF and MEK1 in melanomas and show that the presence of a downstream mutation in MEK1 does not necessarily make BRAF–mutant melanomas resistant to BRAF inhibitors... - The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrationsBegona Comin-Anduix
Department of Surgery, Division of Surgical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California 90095 1782, USA
Clin Cancer Res 16:6040-8. 2010..Combining PLX4032 with immunotherapy may allow expanding the durability of responses. The effects of PLX4032 on immune cells were studied to explore the feasibility of future combinatorial approaches with immunotherapy for melanoma... - Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistanceHubing Shi
Division of Dermatology, Department of Medicine, University of California, Los Angeles, 52 121 CHS, 10833 Le Conte Avenue, California 90095 1750, USA
Nat Commun 3:724. 2012..Thus, alternative clinical strategies may potentially overcome distinct modes of extracellular signal-regulated kinase reactivation underlying acquired B-RAF inhibitor resistance in melanoma... - Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaBegona Comin-Anduix
Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
PLoS ONE 5:e12711. 2010.... - Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationRamin Nazarian
Division of Dermatology Department of Medicine, UCLA s Jonsson Comprehensive Cancer Center, 52 121 CHS, Los Angeles, California 90095 1750, USA
Nature 468:973-7. 2010.... - CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humansRong Rong Huang
Division of Hematology Oncology, 11 934 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
Clin Cancer Res 17:4101-9. 2011..A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses... - CTLA4 blockade increases Th17 cells in patients with metastatic melanomaErika von Euw
Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
J Transl Med 7:35. 2009..We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature... - T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapyJon G Quatromoni
Department of Surgery, University of California, Los Angeles, CA 90095, USA
J Transl Med 10:127. 2012..These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer... - Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032Jonas N Søndergaard
Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
J Transl Med 8:39. 2010..In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity... - The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunityRobert M Prins
Division of Neurosurgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles UCLA, CA 90095, USA
J Immunol 176:157-64. 2006..Nevertheless, immunotherapeutic targeting of malignant CNS tumors may be enhanced by the administration of the innate immune response modifier imiquimod... - Immune rejection in a humanized model of murine prostate cancerDorthe Schaue
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1714, USA
Anticancer Res 30:409-14. 2010..Background/Aim: We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice... - Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathwayVeerauo V Konkankit
Graduate Program in Physiological Sciences, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California, 90095, USA
J Transl Med 9:192. 2011..However, the absence of well-characterized, highly immunogenic tumor-rejection antigens (TRA) in gliomas has limited the implementation of targeted immune-based therapies... - siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomideJonathan E Zuckerman
Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, Los Angeles, California 90095 1782, USA
J Invest Dermatol 131:453-60. 2011..In conclusion, siRNA-mediated RRM2 knockdown significantly inhibits proliferation of melanoma cell lines with different oncogenic mutations with synergistic enhancement in combination with temozolomide... - Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapyChao Ma
1NanoSystems Biology Cancer Center, 2Division of Chemistry and Chemical Engineering, 3Division of Physics, Mathematics, and Astronomy, and 4Division of Biology, California Institute of Technology, Pasadena and 5David Geffen School of Medicine, the Jonsson Comprehensive Cancer Center, and 6Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, California
Cancer Discov 3:418-29. 2013..This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy... - Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse modelsFrédéric D Birkhäuser
Institute of Urologic Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
J Immunother 36:102-11. 2013.... - Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interactionAli R Jazirehi
Department of Surgery, Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA
Cancer Res 71:1406-17. 2011..Though unresponsive to CTL, our results argue that resistant cells can be resensitized to immunotherapy with coadministration of targeted inhibitors to antiapoptotic survival pathways... - Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene deliveryRichard C Koya
Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
J Immunother (1997) 26:451-60. 2003.... - The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectorsRenata Stripecke
Institute for Genetic Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
Blood Cells Mol Dis 31:28-37. 2003..Therefore, lentiviral vectors offer a simple, versatile, and reliable approach for engineering leukemic cells for use as cell vaccines... - Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitroRichard C Koya
Department of Medicine, UCLA-Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
Hum Gene Ther 15:733-48. 2004..This article demonstrates the proof-of-concept to genetically convert monocytes to DC-type antigen-presenting cells with lentiviral vectors... - Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cellsDimitrios N Vatakis
Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles CA 90095, USA
Proc Natl Acad Sci U S A 108:E1408-16. 2011..These studies present a potential therapeutic approach and an important tool to understand better and to optimize the human immune response to melanoma and, potentially, to other types of cancer...